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ABSTRACT: The reactivity of hydrogen peroxide and catalytic hydroiodic acid towards 3,6-dimethoxy-2-(cycloamino)ani-
lines is tunable to give ring-fused benzimidazoles or 1,4,6,9-tetramethoxyphenazine in high yield. Mechanisms via a detected 
nitroso-intermediate are proposed for oxidative cyclization and the unexpected intermolecular displacement of the oxazine. 
An aqueous solution of molecular iodine is capable of the same transformations.   Oxidative demethylation gave targeted ben-
zimidazolequinones, including without cleavage of the incorporated oxetane.
Morpholine is prevalent in marketed drugs.1 The replace-
ment of functional groups with morpholine can increase 
metabolic stability and hydrophilicity.2,3  Oxetane is a cyclic 
ether with similar hydrogen bonding avidity to morpholine, 
which has emerged as a polar alternative to the gem-dime-
thyl group in medicinal chemistry.4,5 NAD(P)H:quinone oxi-
doreductase 1 (NQO1) is a reductase over-expressed in 
many solid tumours.6,7 Benzimidazolequinones are re-
ported excellent substrates for NQO1, which was demon-
strated using recombinant human NQO1.8 Computational 
docking has shown that a polar group (e.g. cyclic ether) four 
or five bonds away from the quinone functional group can 
lead to more efficient NQO1 binding.9 This led us to target 
morpholine and spirocyclic oxetane ring-fused benzimidaz-




Figure 1. Synthetic targets. 
Hydrogen peroxide is a cheap, low molar mass, odorless, 
and eco-friendly oxidant with high atom economy. H2O2 is 
an established mediator for the oxidative cyclization of o-
cyclic amine substituted anilines to give ring-fused benzim-
idazoles.10-15 We have shown that when H2O2 is combined 
with HX (where X = Cl or Br), the oxidative cyclization can 
be accompanied by a selective aromatic halogenation in 
one-pot.13 When the same H2O2 and HX system was applied 
to 3,6-dimethoxy-2-(cycloamino)anilines, a tunable one-pot 
transformation was established (Scheme 1(b)).15  
Scheme 1. H2O2 and HX-Mediated Transformations. 
 
A higher molar ratio of H2O2 relative to HX resulted in halo-
genation and oxidative cyclization, while lower relative 
amounts of H2O2 to HX mediated one-pot halogenation, cy-
clization and quinone formation, generating halogenated 
ring-fused benzimidazolequinones. A larger proportion of 
the hydrohalic acid relative to hydrogen peroxide favors 
halogen (X2) formation (Scheme 1(a)), and molecular chlo-
rine and bromine in water were shown to independently 
mediate the six-electron oxidative transformation to give 
the halogenated ring-fused benzimidazolequinones. The 
 
use of hydroiodic acid (HI) is preferred over the other hy-
drohalic acids for the synthesis of targets 1 and 2, since the 
oxidative cyclization is more likely to occur without halo-
genation, as the electrophilicity of the halogens decreases 
from Cl2>Br2>I2.16 Herein, the reactivity of 3,6-dimethoxy-2-
(cycloamino)anilines using H2O2 and a catalytic amount of 
HI in ethyl acetate is shown to be tunable to favor either the 
intramolecular reaction to give ring-fused benzimidazoles 
or the unexpected intermolecular reaction to give 1,4,6,9-
tetramethoxyphenazine (Scheme 1 (c)). 
The four-step synthesis of ring-fused benzimidazolequi-
nones 1 and 2 began with nucleophilic aromatic substitu-
tion (SNAr) of morpholine and 2-oxa-7-azaspiro[3.5]non-
ane17 onto 1,4-dimethoxy-2,3-dinitrobenzene. The substitu-
tion using bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethane-
dioate gave 7-(3,6-dimethoxy-2-nitrophenyl)-2-oxa-7-
azaspiro[3.5]nonane (3) in 68% yield, when using K2CO3 (4 
equiv) in a 5:1 acetonitrile:water mixture (Scheme 2). Re-
duction of nitrobenzenes with iron powder gave the aniline 
oxidative cyclization precursors in high yields with 3,6-di-
methoxy-2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (4b) 
formed in 80% yield.   
Scheme 2. Preparation of 3,6-Dimethoxy-2-(2-oxa-7-
azaspiro[3.5]nonan-7-yl)aniline (4b). 
        
With 3,6-dimethoxy-2-(morpholin-4-yl)aniline (4a)15 and 
spirocyclic oxetane analogue 4b in hand, the oxidative cy-
clization using H2O2 and HI was investigated (Table 1). In 
keeping with the principles of green chemistry, ethyl ace-
tate was chosen as the reaction solvent.14,18 Morpholine 4a 
did not undergo any transformation in EtOAc at reflux in the 
presence of H2O2 (20 equiv) alone. Addition of one stoichio-
metric equivalent of HI gave after 1 hour, 6,9-dimethoxy-
3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole (5a) in 
56% yield along with an unexpected orange precipitate. 
Spectroscopic data identified the precipitate as 1,4,6,9-tet-
ramethoxyphenazine (6), formed in 25% yield. Using less 
than stoichiometric amounts of HI (0.2 equiv), increased the 
yield of the desired benzimidazole 5a to 69%, and less 
phenazine 6 formed in 19% yield. Using these conditions on 
substrate 4b gave spirocyclic oxetane ring-fused benzimid-
azole 5b in 74% yield with 11% phenazine 6 formed. The 
amount of phenazine 6 (12% yield) was consistent for other 
six-membered cyclizations, as demonstrated by conversion 
of 3,6-dimethoxy-2-(piperidin-1-yl)aniline (4c) to give 6,9-
dimethoxy-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazole 
(5c) in 72% yield. Variation of ring-sizes was investigated, 
with the five- and seven-membered cyclizations of 3,6-di-
methoxy-(2-pyrrolidin-1-yl)aniline (4d) and 2-(azepan-1-
yl)-3,6-dimethoxyaniline (4e) proceeding in high yield to 
respectively give 5,8-dimethoxy-2,3-dihydro-1H-pyr-
rolo[1,2-a]benzimidazole (5d) and 1,4-dimethoxy-7,8,9,10-
tetrahydro-6H-azepino[1,2-a]benzimidazole (5e) in 89% 
and 91% yield. The absence of phenazine 6 from the latter 
reactions is consistent with previous observations of six-
membered oxidative cyclizations being more difficult than 
those forming five and expanded ring-fused benzimidazole 
analogues.14 For all reactions, chromatography was not re-
quired, with residues triturated in diethyl ether to afford 
benzimidazoles 5a-5e.  
Phenazine is the scaffold of secondary metabolites from 
Pseudomonas and Streptomyces with many natural and un-
natural examples having potent biological activity, notably 
anti-cancer.19,20 The oldest synthesis is the Wohl-Aue reac-
tion,21 which is known to be low-yielding, and reported to 
give 1,4,6,9-tetramethoxyphenazine (6) in 10% yield using 
potassium hydroxide in benzene (Scheme 3).22 We at-
tempted to improve this condensation of the aniline with ni-
trobenzene by using potassium tert-butoxide as base in tol-
uene,23 but the yield of 6 remained low, at 34%. We set 
about establishing a more facile route to 6 through manip-
ulation of the optimized H2O2 and HI-mediated oxidative cy-
clization conditions for morpholine 4a (Table 1). Given that 
phenazine 6 formation is an intermolecular reaction, it 
seemed plausible that the use of more concentrated condi-
tions (less ethyl acetate) would lead to increased yields of 6. 
This was indeed the case when reducing the amount of sol-
vent by 4-fold, phenazine 6 became the major product in 
47% yield with benzimidazole 5a formed in 28% yield. The 
H2O2 and HI-mediated cyclization seemed to give the ther-
modynamic product, since the yield of cyclized benzimidaz-
ole 5a became increasingly insignificant (4% then 2%), 
when reducing the reaction temperature from reflux to 40 
°C to room temperature with phenazine 6 isolated in excel-
lent yield of 82%. The requirement for higher temperatures 
for the cyclization may also be due to the nature of the oxi-
dizing system, although hypoiodous acid (HOI) is formed, 
the mediating oxidant is unknown.24,25   
Phenazine 6 was not formed when replacing HI (0.2 equiv) 
with HCl (0.2 equiv) (Scheme 4(a)). Under these conditions 
mainly recovered 4a was observed with 4-chloro-3,6-di-
methoxy-2-(morpholin-4-yl)aniline (4f) formed in 17% 
yield. The regioselectivity of the chlorination was confirmed 
by X-ray crystallography (Scheme 4(b) and Figure S1). The 
yield of chlorinated aniline 4f increased to 76% through use 
of a stoichiometric equivalent of HCl with H2O2. The greater 
reactivity of catalytic amounts of HI relative to HCl, reflects 
the lower pKa of HI,26 and relative ease of oxidation of io-
dine,27 which allows facile breakdown of H2O2.24,25 
 




aConditions: Aniline (1.0 mmol), H2O2 (20.0 mmol), EtOAc (40 mL). bIsolated. cPrecipitate. dEtOAc (10 mL). e40 °C. frt.
Scheme 3. Wohl-Aue Reaction.a  
 
Recently, chlorine (50 equiv) and bromine (50 equiv) with 
water (100 equiv) have been established as mediators for 
six-electron oxidation, converting 3,6-dimethoxy-2-(cy-
cloamino)anilines into cyclized benzimidazolequinones 
(Scheme 1(b)).15 Molecular iodine is however, a less power-
ful oxidizing agent,27 and using the latter conditions did not 
give benzimidazolequinones, but mixtures of difficult to 
separate iodinated aromatics. In the iodine-mediated reac-
tions, ethyl acetate was replaced by acetonitrile, since the 
former solvent is immiscible with water. Using iodine (10 
equiv) in 20% aqueous acetonitrile, a 4-electron oxidation 
occurred in 10 minutes to give cyclized non-iodinated ben-
zimidazoles (Scheme 4(c)). Morpholine 4a and pyrrole 4d 
were converted to 6,9-dimethoxy[1,4]oxazino[4,3-a]ben-
zimidazole (5a) and 5,8-dimethoxypyrrolo[1,2-a]benzimid-
azole (5d) in 48% and 92% yield respectively. Similar to the 
H2O2 and HI-mediated reaction, the five-membered cycliza-
tion was regioselective, and did not give phenazine, how-
ever the less favored morpholine cyclization gave side-
products, including 6 in 6% yield. Presumably for iodine in 
water, the concentration of HOI is greater than in the H2O2 
and HI-mediated reactions (in Table 1) resulting in intrac-
table iodinated side-products. 
Scheme 4. Alternative Oxidative Conditions and X-ray 
Crystal Structure with Cyclization of 4-Chloro-3,6-di-
methoxy-2-(morpholin-4-yl)aniline (4f) (Thermal El-







Entry Aniline Y n HI (mmol) Time (h)  Yield of 5a-5e (%)b Yield of 6 (%)b, c 
1 4a  O 1              0.0       16                5a, 0                 0 
2 4a  O 1              1.0         1                5a, 56               25 
3 4a          O 1              0.2         1                5a, 69               19 
4 4b  
 
1              0.2         1                5b, 74               11 
5 4c          CH2 1              0.2         1                5c, 72               12 
6 4d          CH2 0              0.2         1                5d, 89                 0 
7 4e          CH2 2              0.2         1                5e, 91                 0 
8 4a          O 1              0.2d         1                5a, 28               47 
9 4a  O 1              0.2d, e       16                5a, 4               79 
10 4a  O 1              0.2d, f       24                5a, 2               82 
 













Common to the oxidative cyclization of o-cyclic amine sub-
stituted anilines to give benzimidazoles,10,28 and the Wohl-
Aue and other phenazine syntheses,19,20,29 is the likelihood 
of a nitroso-intermediate. Transformations via the N-oxide 
of the tert-amine of 4a are unlikely, with amine N-oxides 
isolated intermediates only when the primary NH2 is deac-
tivated to an acetamide.30,31 We were however unable to iso-
late a nitroso-intermediate, although encouragingly GC-MS 
of the reaction mixture (entry 10, Table 1) after 1 hour re-
vealed an EI-MS fragmentation pattern supporting the for-
mation of intermediate 7 (Figure S2, Scheme 5). The exist-
ence of highly reactive nitroso-intermediate 7 is supported 
by Meth-Cohn, who also refuted claims of isolations of o-ni-
troso-tert-anilines, including the nitrosation of p-benzyl-
dimethylaniline, which gave only the nitro-compound.32 Ni-
troso 7 should undergo a formal 1,5-hydride shift to the 
likely hydroxylamine 8,28,32-34 which subsequently cyclizes 
and is oxidized to give benzimidazole 5a. The unexpected 
1,4,6,9-tetramethoxyphenazine (6) formation via nitroso 
intermediate 7 would involve intermolecular reaction of 7 
with starting aniline 4a resulting in nucleophilic aromatic 
substitution adduct 10. The proposed formation of iodide 
11 is reminiscent of the Bamberger-Ham reaction for mak-
ing phenazine-N-oxides,35 where two nitrosobenzenes sub-
stituted with para-electron-donating (through resonance) 
groups condense under acidic conditions.19,20 It is known 
that HOI reacts with H2O2 via a reduction to generate addi-
tional HI,24,25 which would favor conversion of 10 to 11. Fur-
ther the yield of phenazine 6 is increased when using a full 
equivalent of HI (entry 2, Table 1). Similar to the conversion 
of hydroxylamine salts 9 and 11 into products 5a and 6 re-
spectively, Nguyen et al. also proposed iodide as a direct re-
ductant for removal of oxygen in iodine-catalyzed reductive 
cyclizations of o-nitro-tert-anilines to give benzimidaz-
oles.33 The necessity for the electron-donating (OMe) group 
in our H2O2 and HI-mediated synthesis of phenazine was in-
vestigated using 2-(morpholin-4-yl)aniline (12a)13 and 2-
(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline (12b), prepared 
from 1-fluoro-2-nitrobenzene (Scheme 6). In both cases, ox-
idative cyclization adducts (13a33 and 13b) were exclu-
sively isolated in moderate yields (67 and 70%) after col-
umn chromatography with phenazine 1436 not observed. 
The presence of appropriately positioned OMe groups does 
not however guarantee phenazine formation. Surprisingly 
chloride 4f exclusively cyclized to give 7-chloro-6,9-di-
methoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidaz-
ole (5f) in 79% isolated yield (Scheme 4(b)), using the H2O2 
and HI reaction conditions (in Table 1), which favored for-
mation of 6. Presumably electronic effects of the Cl substit-
uent circumvent the SNAr step (in Scheme 5). 
 
Scheme 6. Preparation of 2-(2-Oxa-7-azaspiro[3.5]nonan-7-
yl)aniline (12b) and Oxidative Cyclizations. 
 
The structure of 6’,9’-dimethoxy-1’,2’-dihydro-4’H-
spiro[oxetane-3,3’-pyrido[1,2-a]benzimidazole] (5b) was 
confirmed by X-ray crystallography prior to being subjected 
to oxidative demethylation (Scheme 7 and Figure S3). The 
hypervalent iodine reagent [bis(trifluoroacetoxy)iodo]ben-
zene (PIFA) in water at room temperature is reported to 
convert p-dimethoxybenzenes to quinones.37 This mild pro-
cedure was used to give target ether-containing ring-fused 
benzimidazolequinones 1 and 2 in 74% and 78% yield from 
6,9-dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzim-
idazole (5a) and spirocyclic oxetane ring-fused benzimidaz-
ole (5b) respectively. Importantly, PIFA unlike other oxi-
dants,38,39 had no apparent adverse effect on the integrity of 
the oxetane motif. 
In summary, H2O2 and HI-mediated oxidative cyclization of 
3,6-dimethoxy-2-(cycloamino)anilines to give the ring-
fused benzimidazoles can be tuned to alternatively give 
1,4,6,9-tetramethoxyphenazine (6) in high yield. Phenazine 
formation is however not ubiquitous and competes with the 
 
six-membered cyclization only when the 3,6-dimethoxy-2-
(cycloamino)anilines are suitably activated. The detection 
of nitroso-intermediate 7, has led to a proposed mechanism 
for this new HI-catalyzed reaction. Future work will estab-
lish the anti-tumor activity and NQO1 specificity of the syn-
thesized benzimidazolequinones. 
 
Scheme 7. Oxidative Demethylation and X-ray Crystal 
Structure of 6’,9’-Dimethoxy-1’,2’-dihydro-4’H-
spiro[oxetane-3,3’-pyrido[1,2-a]benzimidazole] (5b) 





All chemicals were obtained from commercial sources and 
used without further purification. 1,4-Dimethoxy-2,3-dini-
trobenzene was prepared from 1,4-dimethoxybenzene 
(Sigma Aldrich, 99% (GC)) and nitric acid (Honeywell Fluka, 
64-66%).40 Bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethane-
dioate was prepared using the procedure described by our 
group.17 The preparations of 3,6-dimethoxy-2-(morpholin-
4-yl)aniline (4a), 3,6-dimethoxy-2-(piperidin-1-yl)aniline 
(4c), 3,6-dimethoxy-2-(pyrrolidin-1-yl)aniline (4d)  and 2-
(azepan-1-yl)-3,6-dimethoxyaniline (4e) were previously 
reported using the SNAr of morpholine (Alfa Aesar, 99%), 
piperidine (Sigma Aldrich, 99%), pyrrolidine (Acros, 
+99%), and azepane (Fluorochem, >98%) respectively onto 
1,4-dimethoxy-2,3-dinitrobenzene, followed by reduction 
with iron powder (Alfa Aesar, reduced, 99%).14,15 2,5-Di-
methoxyaniline was prepared by the reduction of 1,4-di-
methoxy-2-nitrobenzene (TCI, >99.0% (GC)) using iron 
powder.41 2-(Morpholin-4-yl)aniline (12a)13 was prepared 
by the SNAr of morpholine onto 1-fluoro-2-nitrobenzene 
(Fluorochem, 99%), followed by reduction with iron pow-
der. H2O2 (Honeywell Fluka, 50% w/v in water, stabilized), 
HI (Sigma Aldrich, 57% w/v in water), HCl (Sigma Aldrich, 
37% w/v in water), I2 (VWR, ≥99%, resublimed), and PIFA 
(Sigma Aldrich, 97%) were used as received. Thin layer 
chromatography (TLC) was performed on TLC silica gel 60 
F254 plates. Flash column chromatography was carried out 
on silica gel (Apollo Scientific 60/40–63 µm).  
Measurements 
Melting points: Melting points were measured on a Stuart 
Scientific melting point apparatus SMP1, except for 1,4,6,9-
tetramethoxyphenazine (6) recorded using differential 
scanning calorimetry (DSC) performed on a Mettler Toledo 
DSC822 differential scanning calorimeter, using standard 
aluminum pans. 
Gas chromatography: GC-MS used to detect the formation 
of nitrosoarene 7 was performed on an Agilent 6890N Se-
ries GC system equipped with an Agilent 5973 Inert Mass 
Selective Detector (EI) and an SGE, 25 m, ID 0.25 mm, FD 
0.25 μm column. The carrier gas used was He at a flow rate 
of 1.3 mL/min. The injector heated to 80 °C and the oven 
temperature increased from 80 to 280 °C at the rate of 10 
°C/min and increased to 320 °C at 40 °C/min.  
Infrared (IR) spectroscopy: IR spectra were recorded us-
ing a Perkin-Elmer Spec 1 with ATR attached.  
Nuclear Magnetic Resonance (NMR) spectroscopy: NMR 
spectra for compounds 2, 3, 4b and 5b were recorded using 
a Jeol ECX 400 MHz instrument equipped with a DEC AXP 
300 computer workstation. NMR Spectra for all other com-
pounds were recorded using a Bruker Avance II 400 MHz 
spectrometer. The chemical shifts are in ppm relative to tet-
ramethylsilane. 13C-NMR spectra at 100 MHz are with com-
plete proton decoupling. NMR assignments are supported 
by Distortionless Enhancement by Polarization Transfer 
(DEPT) and 1H-1H and 1H-13C correlation. 
High resolution mass spectrometry (HRMS): HRMS spec-
tra were obtained using ESI time-of-flight mass spectrome-
ter (TOFMS) on a Waters LCT Mass Spectrometry instru-
ment. The precision of all accurate mass measurements was 
better than 5 ppm.  
X-ray crystallography: A single crystal of 4f was grown 
from CH2Cl2 at 2 °C, and a single crystal of 5b was grown by 
slow evaporation from CH2Cl2. Single crystal data was col-
lected using an Oxford Diffraction Xcalibur system operated 
using the CrysAlisPro software and the data collection tem-
perature was controlled at 298 K using a Cryojet system 
from Rigaku Oxford Diffraction. The crystal structures were 
solved using ShelxT version 2014/55,42 and refined using 
ShelxL version 2017/1,43 both of which were operated 
within the Oscail software package.44 Crystallographic data 
for compounds 4f and 5b was deposited with the Cam-
bridge Crystallographic Data Centre with deposit number of 
CCDC 1917886 and CCDC 1917885 respectively. This data 
is available free of charge via www.ccdc.cam.ac.uk/data_re-
quest/cif (or from the Cambridge Crystallographic Data 
Centre, 12 Union Road, Cambridge CB2 1EZ, U.K.; fax +44 
1223 336033; or e-mail deposit@ccdc.cam.ac.uk). 
Experimental Procedures 
Synthesis of 3,6-Dimethoxy-2-(2-oxa-7-azaspiro[3.5]nonan-
7-yl)aniline (4b). 1,4-Dimethoxy-2,3-dinitrobenzene (0.680 
g, 2.98 mmol), bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) 
ethanedioate (2.053 g, 5.96 mmol) and K2CO3 (1.647 g, 
11.92 mmol) in MeCN (30 mL) and H2O (6 mL) were heated 
at reflux for 40 h. The mixture was evaporated, dissolved in 
EtOAc (30 mL) and washed with brine (3 x 20 mL). The or-
ganic extract was dried (MgSO4), evaporated, and purified 
 
by column chromatography using gradient elution of petro-
leum ether/EtOAc to give 7-(3,6-dimethoxy-2-nitrophenyl)-
2-oxa-7-azaspiro[3.5]nonane (3) (0.624 g, 68%) as a yellow 
solid; Rf 0.44 (1:1 pet. ether/EtOAc); m.p. 125-127 °C; νmax 
(neat, cm-1) 2931, 2861, 2841, 1539 (NO2), 1495, 1381 
(NO2), 1256, 1094, 1057; 1H NMR (400 MHz, CDCl3) δ: 6.83 
(d, J = 9.2 Hz, 1H), 6.74 (d, J = 9.2 Hz, 1H), 4.42 (s, 4H, OCH2), 
3.80 (s, 3H, Me), 3.78 (s, 3H, Me), 2.97-2.90 (br.s, 4H), 1.88-
1.80 (br.s, 4H); 13C{1H} NMR (100 MHz, CDCl3) δ: 152.7, 
144.5, 141.9, 133.9 (all C), 112.9, 109.4 (both CH), 82.1 
(OCH2), 56.8, 56.2 (both Me), 47.8 (CH2), 38.4 (C), 35.6 
(CH2); HRMS (ESI) m/z [M + H]+ Calcd for C15H21N2O5 
309.1449; Found 309.1450. 
Nitrobenzene 3 (0.616 g, 2.00 mmol), iron powder (0.357 g, 
6.40 mmol) and NH4Cl (55 mg, 1.00 mmol) in EtOH (40 mL) 
and H2O (12 mL) were heated at reflux for 18 h. The mixture 
was filtered through Celite®, evaporated, dissolved in EtOAc 
(80 mL) and washed with brine (2 x 60 mL). The organic 
extract was dried (MgSO4), evaporated, and purified by col-
umn chromatography using gradient elution of petroleum 
ether/EtOAc to give 4b (0.445 g, 80%) as an off-white solid; 
Rf 0.33 (3:1 pet. ether/ EtOAc); m.p. 138-140 °C; νmax (neat, 
cm-1) 3444, 3338, 2989, 2917, 2856, 2830, 1605, 1556, 
1490, 1258, 1107; 1H NMR (400 MHz, CDCl3) δ: 6.54 (d, J = 
8.8 Hz, 1H), 6.13 (d, J = 8.8 Hz, 1H), 4.56 (s, 2H, OCH2), 4.40 
(s, 2H, OCH2), 4.37-4.27 (br.s, disappears with D2O, 2H, 
NH2), 3.78 (s, 3H, Me), 3.71 (s, 3H, Me), 3.14 (t, J = 12.1 Hz, 
2H), 2.75 (d, J = 11.4 Hz, 2H), 2.13 (d, J = 12.4 Hz, 2H), 1.79-
1.66 (m, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ: 153.6, 142.1, 
135.4, 126.3 (all C), 107.5, 99.0 (both CH), 82.8, 81.7 (both 
OCH2), 56.1, 55.5 (both Me), 47.3 (CH2), 38.6 (C), 36.7 (CH2); 
HRMS (ESI) m/z [M + H]+ Calcd for C15H23N2O3 279.1709; 
Found 279.1701.  
Synthesis of 2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline 
(12b). 1-Fluoro-2-nitrobenzene (0.296 g, 2.10 mmol), bis(2-
oxa-7-azaspiro[3.5]nonan-7-ium) ethanedioate (0.722 g, 
2.10 mmol) and K2CO3 (1.161 g, 8.40 mmol) in MeCN (20 
mL) and H2O (4 mL) were heated at reflux for 5 h. The mix-
ture was evaporated, dissolved in EtOAc (20 mL) and 
washed with brine (3 x 20 mL). The organic extract was 
dried (MgSO4), evaporated, and purified by column chroma-
tography using gradient elution of petroleum ether/EtOAc 
to give 7-(2-nitrophenyl)-2-oxa-7-azaspiro[3.5]nonane 
(0.489 g, 94%) as an orange solid; Rf 0.38 (3:2 pet. 
ether/EtOAc); m.p. 95-96 °C; νmax (neat, cm-1) 2931, 2859, 
2814, 1603, 1567, 1519 (NO2), 1488, 1463, 1444, 1384, 
1343 (NO2), 1298, 1234, 1167, 1129; 1H NMR (400 MHz, 
CDCl3) δ: 7.76 (dd, J = 8.1, 1.6 Hz, 1H), 7.48-7.43 (m, 1H), 
7.11 (dd, J = 8.3, 1.1 Hz, 1H), 7.05-7.00 (m, 1H), 4.48 (s, 4H, 
OCH2), 2.95 (t, J = 5.5 Hz, 4H), 2.02 (t, J = 5.5 Hz, 4H); 13C{1H} 
NMR (100 MHz, CDCl3) δ: 146.3, 143.3 (both C), 133.4,  
125.9, 121.7, 121.2 (all CH), 81.6 (OCH2), 49.2 (CH2), 38.3 
(C), 34.9 (CH2); HRMS (ESI) m/z [M + H]+ Calcd for 
C13H17N2O3 249.1239; Found 249.1245. 
The above nitrobenzene (0.480 g, 1.94 mmol), iron powder 
(0.347 g, 6.21 mmol) and NH4Cl (52 mg, 0.97 mmol) in EtOH 
(30 mL) and H2O (10 mL) were heated at reflux for 16 h. The 
mixture was filtered through Celite®, evaporated, dissolved 
in EtOAc (60 mL) and washed with brine (2 x 40 mL). The 
organic extract was dried (MgSO4), evaporated, and purified 
by column chromatography using gradient elution of petro-
leum ether/EtOAc to give 12b (0.372 g, 88%) as a pale 
brown solid; Rf 0.35 (3:2 pet. ether/ EtOAc); m.p. 137-139 
°C; νmax (neat, cm-1) 3408, 3325, 3032, 2914, 2856, 2806, 
2740, 2677, 1617, 1501, 1461, 1438, 1425, 1383, 1289, 
1211, 1135, 1125; 1H NMR (400 MHz, CDCl3) δ: 6.94-6.86 
(m, 2H), 6.74-6.65 (m, 2H), 4.46 (s, 4H, OCH2), 4.02-3.87 
(br.s, disappears with D2O, 2H, NH2), 2.89-2.60 (br.s, 4H), 
2.06-1.86 (br.s, 4H); 13C{1H} NMR (100 MHz, CDCl3) δ: 141.6, 
139.6 (both C), 124.6, 119.8, 118.5, 115.1 (all CH), 81.9 
(OCH2), 48.7 (CH2), 38.6 (C), 35.9 (CH2); HRMS (ESI) m/z [M 
+ H]+ Calcd for C13H19N2O 219.1497; Found 219.1487. 
H2O2 and HX-Mediated Transformations 
Reaction conditions are given in Table 1 and Schemes 4(b), 
and 6 for H2O2 and HI, and in Scheme 4(a) for H2O2 and HCl. 
H2O2 and HX were sequentially added dropwise to a stirred 
solution of the anilines (1 mmol) in EtOAc (10 or 40 mL) at 
the indicated reaction temperatures. For the room temper-
ature reaction of aniline 4a, the addition of H2O2 and HI 
were done over ice, and the mixture was then allowed to 
warm to room temperature. At the end of the reaction, the 
solution was filtered, and the orange precipitate washed 
with EtOAc (30 mL) to give 1,4,6,9-tetramethoxyphenazine 
(6). The filtrate was washed with Na2CO3 (satd., 60 mL), and 
dried (MgSO4). The organic extract was evaporated, and the 
residue triturated from Et2O to give benzimidazoles 5a-5d. 
Azepane 5e did not require purification. The residues of 4f, 
5f, 13a and 13b were purified by column chromatography 
using gradient elution of petroleum ether/EtOAc.  
6,9-Dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimid-
azole (5a) (0.161 g, 69%, Table 1, entry 3); pale brown solid; 
m.p. 109-111 °C; vmax (neat, cm-1) 2929, 2827, 1523, 1475, 
1440, 1426, 1402, 1316, 1259, 1227, 1193, 1165, 1119, 
1103, 1084; 1H NMR (400 MHz, CDCl3) δ: 6.45 (ABq, J = 8.6 
Hz, 2H), 4.92 (s, 2H, 1-CH2), 4.41 (t, J = 5.2 Hz, 2H), 4.03 (t, J 
= 5.2 Hz, 2H), 3.87 (s, 3H, Me), 3.79 (s, 3H, Me); 13C{1H} NMR 
(100 MHz, CDCl3) δ: 146.3, 145.8, 141.8, 134.4, 125.0 (all C), 
102.8, 102.0 (both CH), 65.5 (1-CH2), 64.3 (CH2), 55.9, 55.8 
(both Me), 44.9 (CH2); HRMS (ESI) m/z [M+H]+ Calcd for 
C12H15N2O3 235.1083; Found 235.1081, and 1,4,6,9-tetra-
methoxyphenazine (6) (29 mg, 19%); orange solid; m.p. 
(DSC) onset 351.2 °C, peak max 355.9 °C (lit m.p.26 >360 °C); 
νmax (neat, cm-1) 3075, 3010, 2900, 2833, 1177, 1622, 1492, 
1456, 1445, 1437, 1322, 1266, 1248, 1197, 1157, 1127, 
1109; 1H NMR (400 MHz, CDCl3) δ: 6.97 (s, 4H), 4.09 (s, 12H, 
Me); 13C{1H} NMR (100 MHz, CDCl3) δ: 148.8, 135.6 (both C), 
106.0 (CH), 56.1 (Me); HRMS (ESI) m/z [M + H]+ Calcd for 
C16H17N2O4 301.1188; Found 301.1179. 
6’,9’-Dimethoxy-1’,2’-dihydro-4’H-spiro[oxetane-3,3’-pyrido-
[1,2-a]benzimidazole] (5b) (0.203 g, 74%); off-white solid; 
m.p. 166-167 °C; νmax (neat, cm-1) 3004, 2931, 2865, 2837, 
1810, 1606, 1523, 1441, 1260, 1223, 1100, 1082; 1H NMR 
(400 MHz, CDCl3) δ: 6.47 (s, 2H), 4.53 (ABq, J = 6.1 Hz, 4H, 
OCH2), 4.45 (t, J = 6.3 Hz, 2H, 1´-CH2), 3.92 (s, 3H, Me), 3.83 
(s, 3H, Me), 3.32 (s, 2H, 4´-CH2), 2.34 (t, J = 6.3 Hz, 2H, 2´-
CH2); 13C{1H} NMR (100 MHz, CDCl3) δ: 148.2, 145.6, 141.8, 
135.0, 125.3 (all C), 102.6, 101.8 (both CH), 80.8 (OCH2), 
55.93, 55.89 (both Me), 41.7 (1´-CH2), 37.7 (C), 35.0 (4´-
CH2), 31.3 (2´-CH2); HRMS (ESI) m/z [M + H]+ Calcd for 
C15H19N2O3 275.1396; Found 275.1380, and 1,4,6,9-tetra-
methoxyphenazine (6) (17 mg, 11%). 
 
6,9-Dimethoxy-1,2,3,4-tetrahydropyrido[1,2-a]benzimidaz-
ole (5c) (0.167 g, 72%); brown solid; spectral data and melt-
ing point consistent with the literature,14 and 1,4,6,9-tetra-
methoxyphenazine (6) (18 mg, 12%). 
5,8-Dimethoxy-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazole 
(5d) (0.194 g, 89%); off-white solid; spectral data and melt-
ing point consistent with the literature.14 
1,4-Dimethoxy-7,8,9,10-tetrahydro-6H-azepino[1,2-a]ben-
zimidazole (5e) (0.224 g, 91%); brown oil; spectral data 
consistent with the literature.14 
4-Chloro-3,6-dimethoxy-2-(morpholin-4-yl)aniline (4f) 
(0.207 g, 76%); Rf 0.51 (1:1 pet. ether/EtOAc); pale brown 
solid; m.p. 149-151 °C; νmax (neat, cm-1) 3434, 3335, 2960, 
2909, 2881, 2843, 1596, 1549, 1480, 1456, 1445, 1419, 
1261, 1177, 1153, 1041; 1H NMR (400 MHz, CDCl3) δ: 6.65 
(s, 1H), 3.98-3.88 (br.s, 2H), 3.87 (s, 3H, Me), 3.81 (s, 3H, 
Me), 3.78-3.63 (br.s, 2H), 3.52-3.35 (br.s, 2H), 2.87-2.68 
(br.s, 2H), NH2 is absent; 13C{1H} NMR (100 MHz, CDCl3) δ: 
148.9, 143.6, 133.7, 130.5, 114.8 (all C), 109.3 (CH), 68.4 (2 
x CH2), 61.8, 56.0, (both Me), 51.0 (2 x CH2); HRMS (ESI) m/z 
[M + H]+ Calcd for C12H18N2O3Cl 273.1006; Found 273.1012; 
and 6,9-dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]ben-
zimidazole (5a) (9 mg, 4%); Rf 0.35 (EtOAc).  
7-Chloro-6,9-dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-
a]benzimidazole (5f) (0.212 g, 79%); Rf 0.43 (EtOAc); brown 
solid; m.p. 144-146 °C; νmax (neat, cm-1) 2931, 2836, 2359, 
1605, 1508, 1473, 1428, 1399, 1309, 1212, 1153, 1111, 
1070; 1H NMR (400 MHz, CDCl3) δ: 6.64 (s, 1H), 5.00 (s, 2H, 
1-CH2), 4.44 (t, J = 5.2 Hz, 2H), 4.17 (t, J = 5.2 Hz, 2H), 3.96 
(s, 3H, Me), 3.94 (s, 3H, Me); 13C{1H} NMR (100 MHz, CDCl3) 
δ: 147.7, 147.0, 136.7, 133.4, 128.5, 120.5 (all C), 104.8 (CH), 
65.5, 64.1 (CH2), 62.5, 56.1 (both Me), 44.2 (CH2); HRMS 
(ESI) m/z: [M + H]+ Calcd for C12H14N2O3Cl 269.0693; Found 
269.0685.  
3,4-Dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole (13a) 
(0.117 g, 67%); pale brown solid; Rf 0.21 (EtOAc); spectral 
data and melting point consistent with the literature.33 
1',2'-dihydro-4'H-spiro[oxetane-3,3'-pyrido[1,2-a]benzimid-
azole] (13b) (0.149 g, 70%); off-white solid; Rf 0.23 (1:10 
MeOH/EtOAc) m.p. 141-143 °C; νmax (neat, cm-1) 3052, 
2936, 2864, 1668, 1616, 1516, 1485, 1457, 1417, 1371, 
1344, 1319, 1283, 1228, 1161; 1H NMR (400 MHz, CDCl3) δ: 
7.73-7.67 (m, 1H), 7.33-7.28 (m, 1H), 7.28-7.22 (m, 2H), 
4.59 (ABq, J = 6.2 Hz, 4H, OCH2), 4.14 (t, J = 6.3 Hz, 2H, 1’-
CH2), 3.40 (s, 2H, 4’-CH2), 2.47 (t, J = 6.3 Hz, 2H, 2’-CH2); 
13C{1H} NMR (100 MHz, CDCl3) δ: 149.5, 143.2, 134.3 (all C), 
122.4, 122.2, 119.2, 108.9 (all CH), 80.6 (OCH2), 38.8 (1’-
CH2), 38.0 (C), 34.9 (4’-CH2), 30.7 (2’-CH2); HRMS (ESI) m/z 
[M + H]+ C13H15N2O Calcd for 215.1184; Found 215.1180. 
Modified Wohl-Aue Reaction 
Reaction conditions are given in Scheme 3. At the end of the 
reaction, the mixture was filtered, and the precipitate 
washed with water (30 mL) to give 6 (1.02 g, 34%) as an 
orange solid. Spectral data and melting point of phenazine 
6 is consistent with the above.  
Aqueous I2-mediated transformations 
Anilines (1.00 mmol) in MeCN (10 mL) and H2O (2 mL) were 
heated to reflux. I2 (10.00 mmol) was added, and the mix-
ture was stirred at reflux for 10 min. The mixture was fil-
tered, and the precipitate washed with water (20 mL) to 
give phenazine 6. The filtrate was washed with Na2CO3 
(satd., 20 mL) and Na2S2O3 (1 M, 20 mL), and the organic 
extract was dried (MgSO4) and evaporated to dryness. Ben-
zimidazole 5d did not require purification. The residue of 
benzimidazole 5a was purified by column chromatography 
using gradient elution of petroleum ether/EtOAc. 
6,9-Dimethoxy-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimid-
azole (5a) (0.112 g, 48%), Rf 0.35 (EtOAc); and 1,4,6,9-tetra-
methoxyphenazine (6) (9 mg, 6%). Spectral data and melting 
points for 5a and 6 were consistent with the above. 
5,8-Dimethoxy-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazole 
(5d) (0.201 g, 92%); off-white solid; spectral data and melt-
ing point consistent with the literature.14 
General Procedure for the Synthesis of Quinones 1 and 2.  
Benzimidazole (0.26 mmol) and PIFA (0.447 g, 1.04 mmol) 
in H2O (29 mL) and MeOH (0.75 mL) were stirred at room 
temperature for 2 h. The mixture was extracted with CH2Cl2 
(3 x 40 mL). The organic extracts were dried (MgSO4), evap-
orated, and purified by column chromatography using gra-
dient elution of petroleum ether/EtOAc and EtOAc/MeOH.  
3,4-Dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole-6,9-dione 
(1) (39 mg, 74%); yellow solid; Rf 0.41 (EtOAc); m.p. (de-
comp. >165 °C); νmax (neat, cm-1) 2924, 1664 (C=O), 1584, 
1531, 1475, 1436, 1379, 1345, 1317, 1289, 1225, 1202, 
1112, 1095, 1066; 1H NMR (400 MHz, CDCl3) δ: 6.68 (ABq, J 
= 10.4 Hz, 2H), 4.99 (s, 2H, 1-CH2), 4.44 (t, J = 5.2 Hz, 2H), 
4.14 (t, J = 5.2 Hz, 2H); 13C{1H} NMR (100 MHz, CDCl3) δ: 
180.9, 178.1 (both C=O), 148.0, 141.2 (both C), 136.6, 135.8 
(both CH), 130.1 (C), 65.0 (1-CH2), 63.3, 44.7 (both CH2); 
HRMS (ESI) m/z [M + H]+ C10H9N2O3 Calcd for 205.0613; 
Found 205.0623.  
1’,2’-Dihydro-4’H-spiro[oxetane-3,3’-pyrido[1,2-a]benzimid-
azole]-6’,9’-dione (2) (49 mg, 78%); yellow oil; Rf 0.44 (1:10 
MeOH/EtOAc); νmax (neat, cm-1) 2929, 1661 (C=O), 1510, 
1487, 1446, 1350, 1270, 1202, 1132; 1H NMR (400 MHz, 
CDCl3) δ: 6.62 (ABq, J = 10.4 Hz, 2H), 4.56 (ABq, J = 6.2 Hz, 4H, 
OCH2), 4.38 (t, J = 6.2 Hz, 2H, 1´-CH2), 3.32 (s, 2H, 4´-CH2), 
2.38 (t, J = 6.2 Hz, 2H, 2´-CH2); 13C{1H} NMR (100 MHz, 
CDCl3) δ: 181.1, 178.2 (both C=O), 151.9, 149.9 (both C), 
136.5, 136.0 (both CH), 130.2 (C), 80.5 (OCH2), 41.7 (1´-
CH2), 37.2 (C), 34.4 (4´-CH2), 30.4 (2´-CH2); HRMS (ESI) m/z 
[M + H]+ C13H13N2O3 Calcd for 245.0926; Found 245.0923. 
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